Mukd-546 [hot] 【PREMIUM - 2026】

This study presents a comprehensive pre‑clinical assessment of Mukd‑546, spanning computational modeling, biochemical selectivity profiling, cellular pharmacodynamics, pharmacokinetics, and efficacy in mouse xenograft models.

The MAPK/ERK signaling cascade is frequently hyper‑activated in a wide spectrum of solid tumours, driving uncontrolled proliferation and resistance to conventional chemotherapy. Mukd‑546, a newly synthesized heterocyclic small‑molecule, was designed to selectively inhibit MEK1/2, the central kinases of this pathway. mukd-546

MUKD-546 is available in several digital and physical formats. While the standard version is censored in accordance with Japanese regulations, various "decensored" or "mosaic removed" versions have been circulated by third-party groups following the initial release. MUKD-546 is available in several digital and physical

Cells were seeded at 5 × 10³ cells well⁻¹ in 96‑well plates, treated with Mukd‑546 (0.1 nM–10 µM) for 72 h, and MTT (0.5 mg·mL⁻¹) added for 4 h. Absorbance at 570 nm measured cell viability. IC₅₀ values calculated using non‑linear regression (GraphPad Prism). Absorbance at 570 nm measured cell viability

A multi‑stage pre‑clinical program was conducted: (i) in‑silico docking and molecular dynamics to predict binding affinity; (ii) biochemical kinase assays to assess selectivity; (iii) cellular viability, apoptosis, and cell‑cycle analyses in a panel of 12 cancer cell lines; (iv) pharmacokinetic (PK) profiling in Sprague‑Dawley rats; (v) efficacy and safety evaluation in xenograft mouse models of KRAS‑mutant pancreatic ductal adenocarcinoma (PDAC) and BRAF‑mutant melanoma.

The film’s narrative centers on a "casual hookup" or "off-party" scenario where a group of men and women meet with the intent to explore uninhibited sexual desires. The plot emphasizes the transition from the tension of an initial meeting to a wild, collaborative environment. Key thematic elements include: